MALARIA ERADICATION
THROUGH VACCINATION
Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
Sanaria CEO, Dr. Stephen L. Hoffman answers questions about the SANARIA PfSPZ Vaccine on Reddit’s AMA
Update: The Reddit AMA is now closed but you can go back and read it in the archive.
Sanaria’s Malaria Vaccine Yields Unprecedented Protection In Phase 1 Clinical Trial
Results of a phase I clinical trial of the Sanaria® PfSPZ Vaccine to combat malaria, published today in the online issue of Science magazine, show that the vaccine provided complete protection against malaria in subjects who were exposed to Plasmodium falciparum parasites.
Sanaria featured in BBC News story, A Faster Path to a Possible Malaria Vaccine
Malaria kills more than 650,000 people every year and scientists say they are close to finding a vaccine, but the method of testing for a vaccine has long been time-consuming and risky to transport. Now Sanaria, a biotechnology firm based in the US state of Maryland, has developed the first injectable form of malaria, speeding up clinical trials, reducing the time it could take to develop a vaccine and helping researchers more easily share their work. Read more and watch the video from the BBC.
NF135.C10: a new Plasmodium falciparum clone for controlled human malaria infections
Read the new paper published in Journal of Infectious Diseases. Abstract We established a new field clone of Plasmodium falciparum for use in controlled human malaria infections and vaccine studies to complement the current small portfolio of P. falciparum strains, primarily based on NF54. The Cambodian clone NF135.C10 consistently produced gametocytes and generated substantial numbers of sporozoites in Anopheles mosquitoes and diverged from NF54 parasites by genetic markers. In a controlled human malaria infection trial, 3 of 5 volunteers challenged by mosquitoes infected with NF135.C10 and 4 of 5 challenged with NF54 developed parasitemia as detected with microscopy. The 2 strains induced similar clinical signs and symptoms as well as cellular immunological responses.
Injectable parasites controlling infection, featured in Healio
In the latest edition of Healio, the health care specialist publication reports on Sanaria’s abstract at ASTMH and the concept of injectable parasites being able to control malaria infections.
Future Montgomery workforce experiments with science, medicine
Sanaria has been featured in The Washington Post about an event for local students to give them experience with science outside the classroom. Read more about what a great time we had!
An Urgent Need for Malaria Vaccines
Sanaria has an innovative approach to malaria vaccines using Plasmodium falciparum (Pf) sporozoites (SPZ) as the platform technology for immunizing people against malaria infection. The proven effective results of this approach are documented in Sanaria’s publications.
Global Collaboration: The I-PfSPZ Consortium
Semi-annually, Sanaria organizes the international PfSPZ Consortium (i-PfSPZ-C) meeting for our partners, collaborators and funders where we analyze, present and discuss our findings prior to publication. The i-PfSPZ-C allows our collaborators and partners to share their work, modify research and clinical plans based on the consortium efforts and map out future funding needs.
Subscribe
Our Malaria Vaccine Pipeline
Innovative routes to success. A major impact in global health.